Mersana Therapeutics to Present at Upcoming May 2024 Investor Conferences

2024-05-22

抗体药物偶联物

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit Format: Fireside chat Date/Time: Wednesday, May 29, 2024, at 9:00 a.m. Eastern Time Goldman Sachs 45th Annual Global Healthcare Conference Format: Fireside chat Date/Time: Wednesday, June 12, 2024, at 8:00 a.m. Eastern Time Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at Archived replays will be available for approximately 90 days following the events. About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at . Contact: Jason Fredette 617-498-0020 jason.fredette@mersana.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构